Published in Medical Letter on the CDC and FDA, January 11th, 2004
The test method separately detects IgM and IgG antibodies to B. burgdorferi, the infectious tick borne bacteria that cause Lyme disease. The FDA's 510(k) clearance allows the test to be marketed and sold in the U.S. with the label for in vitro diagnostic use.
The BBI Borrelia burgdorferi IgM and IgG Western Blot Test Kit is intended for use in testing human serum samples that have been found positive or equivocal using a first-line test...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.